2006 Will Bring a Significant Change to the Statin Market as Generic Forms of Two of the Top Selling Statins Are Introduced to the U.S. Market.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36149) has announced the addition of The Dyslipidemia Market: Can Growth Be Sustained as Statin Patents Expire? to their offering. Dyslipidemia is a key independent risk factor for cardiovascular disease (CVD CVD Cardiovascular disease, see there ); CVD is the largest therapeutic segment of the world pharmaceutical market, and treatment of dyslipidemia represents a major sector of the CVD market. This report provides an overview of the condition, its role in CVD, and its prevalence. We discuss Dyslipidemia treatments, with a focus on the statins as the dominant treatment choice worldwide. This report reviews key patent expiries, including the imminent U.S. expiries of pravastatin pravastatin /prav·a·stat·in/ (prav´ah-stat?in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the sodium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the (Bristol-Myers Squibb's Pravachol) and simvastatin simvastatin /sim·va·stat·in/ (sim´vah-stat?in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used in the treatment of hypercholesterolemia and other forms of dyslipidemia and to lower the risks associated (Merck & Co.'s Zocor) and the expected 2011 patent expiry of the best-selling statin, atorvastatin atorvastatin /ator·va·stat·in/ (ah-tor?vah-stat´in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the calcium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia. (Pfizer's Lipitor). In addition, we discuss emerging agents in this market, highlighting the effect generic agents may have on their adoption, or the effect these new agents may have on generics erosion of the market. Finally, we present our expectations for the market throughout our 2004-2014 forecast period. The cardiovascular market is the largest therapeutic segment in the world pharmaceutical market. In 2004, sales of cardiovascular drugs exceeded $63.1 billion in the seven major markets that this report covers (United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). Nearly 40% ($24 billion) of those sales were for agents prescribed to treat dyslipidemia, an abnormality in blood lipid levels recognized as an independent risk factor for cardiovascular disease (CVD). IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. reports that, by 2003, agents for the reduction of cholesterol and triglyceride (TG) levels had become the largest selling class of drugs in the world, owing essentially to the sales of six statins. Sales of these agents have seen dramatic growth, increasing at a rate of 14.2% per year from 1998 to 2004. In 2004, global sales of statins reached $22.6 billion, with most of those sales in the United States. Statin sales have been a major growth driver for the companies that market them; however, 2006 will bring a significant change to the market as generic forms of two of the top selling statins, pravastatin (Bristol-Myers Squibb's Pravachol) and simvastatin (Merck & Co.'s Zocor), are introduced to the U.S. market. This report provides an overview of dyslipidemia, its role in CVD, and its prevalence in the seven markets this report covers. The report discusses current treatments for dyslipidemia, with a focus on the statins as the dominant treatment choice worldwide. The author reviews key patent expiries, including the imminent U.S. expiries of pravastatin and simvastatin and the expected 2011 patent expiry of the best-selling statin, atorvastatin (Pfi zer's Lipitor). Emerging agents in this market are also discussed; highlighting the effect generic agents may carry. Contents are as follows:- Statins and the Cardiovascular Market Overview of Dyslipidemia Lipoproteins in the Blood Dyslipidemia and Cardiovascular Disease Prevalence of Dyslipidemia Current Treatments Statins Fibrates Cholesterol Modulators Bile Acid Sequestrants Nicotinic Acid (Niacin niacin: see coenzyme; vitamin. niacin or nicotinic acid or vitamin B3 Water-soluble vitamin of the vitamin B complex, essential to growth and health in animals, including humans. ) Cholesterol Absorption Inhibitors Combination Products Current Market Status United States Europe Japan Key Patent Expiries Agents in Development PPAR PPAR Peroxisome Proliferator Activated Receptor PPAR Physical Partitions Agonists Cholesterol Modulators CETP CETP Cholesteryl Ester Transfer Protein CETP Certified Employee Training Program CETP Common Effluent Treatment Plant CETP China Energy Technology Program CETP Centre de Recherches en Physique de l'Environment Terrestre et Planetaire (French) Inhibitors ACAT ACAT See: Automated Customer Account Transfer Inhibitors Nicotinic Acid Antagonists Squalene squalene (skwäˑ·lēn), n a popular traditional Asian remedy derived from the liver oil of sharks. Synthetase synthetase /syn·the·tase/ (-the-tas) a term used in the names of some of the ligases, no longer favored because of its similarity to synthase and its emphasis on reaction products. syn·the·tase n. Inhibitors Combination Products Lp-PLA2 Inhibitor Statins Market Outlook United States Europe Japan List of Figures For more information visit http://www.researchandmarkets.com/reports/c36149 Source: Decision Resources |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion